WUXI13.BK WuXi Biologics (Cayman) Inc.

Healthcare Biotechnology Thailand Exchange
3.02 THB
Close of Nov 7, 2026
1.80 3.64
Market cap
THB 12.4B
P/E
0.6x
P/B
0.05x
ROE
10.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is WUXI13.BK undervalued?

Graham number

The Graham number of WuXi Biologics (Cayman) Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

WuXi Biologics (Cayman) Inc. fundamental analysis

No fundamental analysis for WuXi Biologics (Cayman) Inc. yet.

WuXi Biologics (Cayman) Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstre…

Full company profile